These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

772 related articles for article (PubMed ID: 11176842)

  • 21. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
    Greenspan SL; Bone HG; Ettinger MP; Hanley DA; Lindsay R; Zanchetta JR; Blosch CM; Mathisen AL; Morris SA; Marriott TB;
    Ann Intern Med; 2007 Mar; 146(5):326-39. PubMed ID: 17339618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population.
    Naves M; Díaz-López JB; Gómez C; Rodríguez-Rebollar A; Rodríguez-García M; Cannata-Andía JB
    Osteoporos Int; 2003 Jul; 14(6):520-4. PubMed ID: 12730754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of Prevalent Vertebral Fractures Predict New Fractures in Elderly Men.
    Karlsson MK; Kherad M; Hasserius R; Nilsson JÅ; Redlund-Johnell I; Ohlsson C; Lorentzon M; Mellström D; Rosengren BE
    J Bone Joint Surg Am; 2016 Mar; 98(5):379-85. PubMed ID: 26935460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determinants of the size of incident vertebral deformities in European men and women in the sixth to ninth decades of age: the European Prospective Osteoporosis Study (EPOS).
    Reeve J; Lunt M; Felsenberg D; Silman AJ; Scheidt-Nave C; Poor G; Gennari C; Weber K; Lorenc R; Masaryk P; Cannata JB; Dequeker J; Reid DM; Pols HA; Benevolenskaya LI; Stepan JJ; Miazgowski T; Bhalla A; Bruges Armas J; Eastell R; Lopes-Vaz A; Lyritis G; Jajic I; Woolf AD; Banzer D; Reisinger W; Todd CJ; Felsch B; Havelka S; Hoszowski K; Janott J; Johnell O; Raspe HH; Yershova OB; Kanis JA; Armbrecht G; Finn JD; Gowin W; O'Neill TW;
    J Bone Miner Res; 2003 Sep; 18(9):1664-73. PubMed ID: 12968676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term morbidity and mortality after a clinically diagnosed vertebral fracture in the elderly--a 12- and 22-year follow-up of 257 patients.
    Hasserius R; Karlsson MK; Jónsson B; Redlund-Johnell I; Johnell O
    Calcif Tissue Int; 2005 Apr; 76(4):235-42. PubMed ID: 15812579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia.
    Seeman E; Devogelaer JP; Lorenc R; Spector T; Brixen K; Balogh A; Stucki G; Reginster JY
    J Bone Miner Res; 2008 Mar; 23(3):433-8. PubMed ID: 17997711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group.
    Genant HK; Jergas M; Palermo L; Nevitt M; Valentin RS; Black D; Cummings SR
    J Bone Miner Res; 1996 Jul; 11(7):984-96. PubMed ID: 8797120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.
    Siris E; Adachi JD; Lu Y; Fuerst T; Crans GG; Wong M; Harper KD; Genant HK
    Osteoporos Int; 2002 Nov; 13(11):907-13. PubMed ID: 12415439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between back pain and future vertebral fracture in postmenopausal women.
    Kuroda T; Shiraki M; Tanaka S; Shiraki Y; Narusawa K; Nakamura T
    Spine (Phila Pa 1976); 2009 Aug; 34(18):1984-9. PubMed ID: 19680106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical treatment of vertebral osteoporosis.
    Lippuner K
    Eur Spine J; 2003 Oct; 12 Suppl 2(Suppl 2):S132-41. PubMed ID: 13680313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.
    Felsenberg D; Miller P; Armbrecht G; Wilson K; Schimmer RC; Papapoulos SE
    Bone; 2005 Nov; 37(5):651-4. PubMed ID: 16126016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis.
    Lindsay R; Pack S; Li Z
    Osteoporos Int; 2005 Mar; 16(3):306-12. PubMed ID: 15455193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incident vertebral fractures and mortality in older women: a prospective study.
    Kado DM; Duong T; Stone KL; Ensrud KE; Nevitt MC; Greendale GA; Cummings SR
    Osteoporos Int; 2003 Jul; 14(7):589-94. PubMed ID: 12827222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
    Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
    Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between osteoporosis and cardiovascular disease in postmenopausal women.
    Tankó LB; Christiansen C; Cox DA; Geiger MJ; McNabb MA; Cummings SR
    J Bone Miner Res; 2005 Nov; 20(11):1912-20. PubMed ID: 16234963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secular trends in the incidence of postmenopausal vertebral fractures.
    Cooper C; Atkinson EJ; Kotowicz M; O'Fallon WM; Melton LJ
    Calcif Tissue Int; 1992 Aug; 51(2):100-4. PubMed ID: 1422947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
    Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
    JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spinal deformity index (SDI) is a good predictor of incident vertebral fractures.
    Kerkeni S; Kolta S; Fechtenbaum J; Roux C
    Osteoporos Int; 2009 Sep; 20(9):1547-52. PubMed ID: 19137350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study.
    Kushida K; Shiraki M; Nakamura T; Kishimoto H; Morii H; Yamamoto K; Kaneda K; Fukunaga M; Inoue T; Nakashima M; Orimo H
    J Bone Miner Metab; 2004; 22(5):462-8. PubMed ID: 15316867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.